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ABSTRACT
We present a case of a young woman, age 34, who pre-
sented with recurrent Lyme neuroborreliosis (LNB). Her 
clinical profile consisted of a rare combination of two third-
stage manifestations, namely, progressive encephalomyelitis 
and peripheral neuritis, in both bouts of the disease. The 
epidemiological data were controversial, as she reported 
a tick bite only two months prior to the onset of symptoms. 
Negative magnetic resonance imaging (MRI) results excluded 
multiple sclerosis, vascular causes and tumours. Serological 
tests confirmed the Bb infection in the recommended two-
step serological approach consisting of an enzyme-linked im-
munosorbent assay (ELISA) test for Borrelia burgdorferi (Bb) 
immunoglobulin G (IgG) and immunoglobulin M (IgM) and 
a Western blot (WB) as confirmatory analysis in the blood. 
Another controversial issue is the lack of pleocytosis. Atypical 
findings in our patient can be explained by a possible rare 
genotype of Bb. After treatment with oral doxycycline, she 
made an apparent remission, but after three months, she had 
another episode with signs of central and peripheral nervous 
system involvement, increased Bb antibodies and white mat-
ter changes on the MRI. This time, she was treated with intra-
venous ceftriaxone, 2 grams daily for four weeks. She showed 
no signs of LNB, both clinically and serologically, during a 
follow up lasting about a year. This case emphasises the im-
portance of the clinical and serological findings and the use of 
ceftriaxone as the first line of treatment in LNB.
Key words: Lyme neuroborreliosis, progressive enceph-
alomyelitis, neuritis, ceftriaxone
SAŽETAK
Mi predstavljamo slučaj mlade žene starosti 34 godine 
sa rekurentnom Lajmskom neuroboreliozom (LNB). Njena 
klinička slika se sastojala od retke kombinacije dve mani-
festacije treće faze, naime, progresivnog encefalomijelitisa 
i perifernog neuritisa u obe epizode bolesti. Epidemiološki 
podaci su kontroverzni jer se ubod krpelja desio samo 
dva meseca ranije. Magnetna rezonanca (MR) mozga je 
isključila multiplu sklerozu, vaskularne uzroke i tumor. 
Serološki testovi su potvrdili Bb infekcije u preporučenoj se-
rologiji u dva koraka, sa enzyme-linked immunosorbent as-
say (ELISA) testom za Borrelia burgdorferi (Bb) specifične 
imunoglobuline G (IgG) i imunoglobulina M (IgM) i Vestern 
Blot (VB) testom za konfirmaciju. Drugo kontroverzno pi-
tanje je nedostatak pleocitoze u likvoru. Atipični nalazi u 
naše bolesnice mogu se objasniti retkim genotipom Bb. Na-
kon tretmana sa oralnim doksiciklinom, bolesnica je postig-
la remisiju, ali je posle tri meseca imala još jednu epizodu 
sa znacima zahvaćenosti centralnog i perifernog nervnog 
sistema, povećanim titrom specifičnih Bb antitela kao i 
promenama bele mase na MR mozga. Ovaj put, ona je tre-
tirana ceftriaksonom intravenski, dva grama dnevno tokom 
četiri nedelje. Bolesnica je ponovo ušla u remisiju  LNB koja 
se održavala i klinički i serološki tokom praćenja u trajanju 
od oko godinu dana. Ovaj slučaj naglašava značaj kliničkih 
i seroloških nalaza u dijagnostici kao i opravdanost ceftri-
aksona, kao prve linije lečenja u LNB.




Lyme neuroborreliosis (LNB) is a disease of the central 
nervous system (CNS) and/or peripheral nervous system 
(PNS) caused by the spirochete Borrelia burgdorferi (Bb) 
as part of a general infection referred to as Lyme borreliosis 
(LB) or Lyme disease (1, 2). In Europe, LNB is caused by Bb 
sensu lato—mainly Borrelia garinii and Borrelia afzelii—
and rarely Bb sensu stricto, whereas in North America, the 
only bacterium is Bb sensu stricto (3, 4).
LB  clinically manifests in the following three stages: first 
or early localised disease, second or early disseminated dis-
ease and the third or late disseminated disease (1, 5). Lyme 
neuroborreliosis  upcomprises 10-15% of all cases of LB.
The first stage
In the first stage of LB, the typical skin manifestation 
is Erythema migrans (EM), a red circle at least 5 cm in 
diameter. As this circle enlarges, its centre becomes pale. 
Neurological disorders are less common in the early stages 
and may manifest by headache, muscle pain and fever, with 
or without EM (6). The titre of antibodies in the blood at 
this stage is negative, and the diagnosis is based solely on 
the identification of the clinical and epidemiological data 
regarding the tick bite.
The second stage
In the second stage of LB, there are neurological, rheu-
matological, cardiac and skin manifestations (4). The most 
typical manifestations of the second stage of LNB  are as 
follows: painful meningoradiculitis or Garin-Bujadoux-
Bannwarth syndrome (GBBS), meningitis, encephalitis, 
cranial mono- and polyneuritis,  and myelitis. Less com-
mon symptoms includelythere is plexitis, myositis, pseu-
dotumour of the brain, vasculitis, ataxia and other clinical 
manifestations (7). 
Painful meningoradiculitis occurs within the first four 
months after the tick bite (4). The position of pain in the 
body changeschanges and arm and leg weakness can occur, 
as well as neck stiffness. Cerebrospinal fluid (CSF) pleocy-
tosis is characteristic with hyperproteinorachia and some-
times a positive oligoclonal response.
The third stage
The third stage of LB consists of neurological, rheu-
matological and dermatological manifestations. The third 
stage may occur without any apparent manifestations of 
the first two stages, and in many cases, patients do not 
recall a tick bite. In the third stage, the most prominent 
clinical entities are progressive encephalomyelitis, en-
cephalopathy, neuropathy (with or without acrodermatitis 
chronica atrophicans), dementia, myositis, granulomatous 
CNS tumour and vasculitis (4).
Progressive encephalomyelitis is characterised by spas-
tic paresis, ataxia, cranial nerve damage (ofnamely, cranial 
nerves VII and VIII), micturition disturbances and other 
signs (8). The CSF signs are pleocytosis, hyperproteinora-
chia, oligoclonal response and intrathecal synthesis of the 
IgG and IgM immunoglobulins es(9). In the case of CNS 
involvement, it is beneficial to perform magnetic reso-
nance imaging (MRI) of the brain and possibly the spinal 
cord (10). It is possible for cranial neuropathy and menin-
gitis to appear on the MRI due to the enhancement after 
contrast application.
Encephalopathy of LNB is expressed byas fatigue, 
memory disturbances, headache, confused state, depres-
sion, daytime sleepiness, irritability and dysnomia (4). ,Ad-
ditionally, there are various neuropsychological deficits 
(11). An MRI can reveal small white matter lesions of the 
brain. Specific antibodies to Bb in the CNS are found in 
50% of these cases.
In neuropathy, muscle stretch reflexes are reduced or 
absent and there is weakness and numbness of the limbs, 
pain and muscle cramps.
Diagnosis of Lyme neuroborreliosis
Microbiological methods of diagnosis, which can prove 
LB , can be direct and indirect (12, 13). Direct diagnos-
tic methods include culturing pathogens in appropriate 
substrates and detection of genetic material (14). Indirect 
methods can confirm infection by the detection of specific 
antibodies (15, 16).
Borrelia cultivation is the best and the only accurate 
evidence of an infection with Bb, especially when Bb is in 
atypical clinical forms and for patients who do not develop 
a proper specific immune response. However, the cultiva-
tion of Bb sensu lato is a very complex and time-consuming 
method (9 weeks and even longer) and can be performed 
only in well-equipped laboratories (12, 17).
It is necessary in the case of suspected LB, based on 
symptoms, to start a serology examination with an en-
zyme-linked immunosorbent assay (ELISA) test for Bb 
immunoglobulin G (IgG) and immunoglobulin M (IgM) 
(4). Determination of rheumatoid factor (RF) and Vene-
real Disease Research Laboratory (VDRL) in the blood is 
mandatory to exclude the most common false-positive 
results: rheumatoid arthritis and syphilis. It is also nec-
essary that the ELISA be positive in at least two differ-
ent samples. If the ELISA is positive, a confirmation test 
is required (because of the possibility of false positive 
results) with Western blot (WB) analysis, which dem-
onstrates the specificity of previous findings (9). False-
positive and/or misinterpreted laboratory findings are 
often the cause of patients wandering from one doctor 
to another doctor and not having adequate support. It is 
suggested that all serological tests are performed using 
both the serum and the CSF (9).
The new European criteria for LNB includes two levels 
of LNB diagnosis: definite and possible LNB (18). A defi-
nite LNB must include at least two of the following three 
criteria: 1. neurological symptoms; 2. CSF pleocytosis; 
and/or 3. intrathecal synthesis of antibodies to Bb. Anti-
bodies may be negative in the first 6  weeks. It is always 
necessary to exclude other causes of current symptoms, 
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as diagnostic errors are common.  I gM has no diagnostic 
value in late LNB, and if it is an isolated finding, it is usu-
ally indicative of a false positive and is thus likely caused 
by some other disease (19). IgM class antibodies appear 
by the third week and IgG antibodies from the sixth week 
after the infected tick bite.
IgG antibodies to Bb usually remain positive through-
out the patient’s life, even after successful treatment of 
Lyme disease (20). IgG and IgM antibodies can persist in 
the CSF long after receiving adequate therapy and showing 
no further evidence of active neurologic disease.
Treatment of Lyme disease and
Lyme neuroborreliosis
Antibiotic therapy is causal treatment for LB and LNB 
(21). It is necessary to perform the correct diagnostic pro-
cedure before treatment to prevent the application of a 
long-term therapy that is inadequate for a disease other 
than LNB. Such a misstep can lead to unnecessary com-
plications.
In the earlier stages of LB, the efficacy of oral doxycy-
cline 100 milligrams every 12 hours daily for 14 days was 
shown to be effective . The drug of choice for the third 
stage of the LNB is ceftriaxone, which is given intravenous-
ly 2 grams a day for three to four weeks (21). Improvement 
in acute cases occurs in a few days and in chronic cases 
after several months or even longer (8 months or more). 
An improvement or cure is found in 90% of cases. Alterna-
tively, intravenous cefotaxime or penicillin or amoxicillin 
orally is given. If there is possible LNB, one course of anti-
biotic therapy is sufficient, and if there is no improvement, 
one should look for other causes. If the criteria have been 
met for definite LNB and the therapy was ineffective after 
more than six months, the condition is called post Lyme 
syndrome (22). In this syndrome, antibiotic therapy is not 
effective. In children younger than 9 years of age, doxycy-
cline is contraindicated.
A CASE REPORT
Our patient was a 34-year-old woman who was admit-
ted to the neurology department of the General Hospital 
Berane on two separate occasions, in April and July of 
2008, suffering from fatigue, headaches, weakness in the 
arms and legs, difficulty walking, ataxia, numbness of the 
face and neck stiffness. Anamnestic data stated a tick bite 
two months before her first admission.
During her first hospitalisation in April, the patient 
complained of malaise, headaches, weakness in the arms 
and legs (difficulty in walking, ataxia), numbness of the 
face and neck stiffness.  Neurological examination on ad-
mission showed she had hypesthesia of the left half of the 
face. Her neck was slightly stiff, but she tested negative for 
meningeal signs. She had weakness in both arms, as well 
as in both legs. Her muscle stretch reflexes were increased 
in all four extremities, and her extended reflex zone was 
found with patellar and feet clonus on both sides. Her 
plantar reflex was absent.
On the basis of the clinical presentation disseminated, 
the CNS disease was supposed and the necessary diag-
nostic procedures were performed. Magnetic resonance 
imaging  of the brain and cervical spine were performed 
in April, and the findings were normal. The ELISA results 
for IgG and IgM antibodies to Bb in serum were posi-
tive and confirmed by WB. The serodiagnosis was con-
firmed positive on several occasions. Control serologic 
tests in May were positive, whereas in June, the findings 
were normal. The cytological findings in the CSF were 
within normal limits. Isoelectric focusing of CSF showed 
normal results. Electromyoneurography (EMNG) of the 
upper and lower extremities indicated predominantly ax-
onal neuropathy, which is aetiologically associated with 
the underlying disease, i.e., LNB. Routine laboratory tests 
showed normal results.
During her first hospitalisation in April, after receiving 
positive serological findings for Bb, the patient received 
doxycycline tablets at a dose of 100 mg per 12 hours for 
one month, after which there was an improvement and a 
reduction of symptoms in May. 
A recurrence of symptoms occurred in July of the same 
year when she was readmitted to the hospital. A neuro-
logical examination revealed the following findings: her 
cranial nerve findings were normal, her meningeal signs 
were negative, she had a slightly stiff neck, both her arms 
and legs were weak predominantly on the left side; her 
muscle stretch reflexes were increased bilaterally and had 
enhanced reflexogenic zone and she had patellar and feet 
clonus present on both sides with a normal plantar reflex.
All routine laboratory tests were within normal range. 
Her brain MRI results revealed the presence of changes in 
the deep paraventricular white matter which correspond-
ed to changes observed in LNB. AnHer ELISA test showed 
a rise in Bb antibody titre of IgG and IgM in serum. ,Ad-
ditionally, a confirmatory WB test in July showed the she 
had increased titres of specific antibodies. New CSF cyto-
logical and biochemical findings and isoelectric focusing 
of CSF again showed normal findings. The EMNG finding 
was unchanged compared to the previous test.
Given that LNB reoccurred despite previous treat-
ment with doxycycline, therapy with ceftriaxone at a 
dose of one gram per 12 hours as an intravenous infu-
sion during four weeks was  administered in July. An im-
provement in symptoms occurred after a few days, and 
the neurological status upon discharge fromafter the 
second hospitalisation showed only increased muscle 
stretch reflex on the left leg.
In August, after one month, follow up controls were 
performed, and then in September, October and Novem-
ber of the same year with normal neurological findings. 
In August and November of 2008 and March of 2009, 
the serological results were negative. Based on clinical 




We presented a case of a female patient with LNB, 
which fulfilled the criteria for the third stage of LNB, 
with progressive encephalomyelitis and neuropathy (4, 
21). AThe short time interval between the occurrence the 
tick bite and the presentation theof the symptoms and the 
dynamics of serology are arguments against a causal re-
lationship, so these occurrence of these issues was most 
likely a coincidence. Therefore, the infection was most 
likely acquired during an earlier infected tick bite that 
had not been registered.
 The visibility of ticks on the skin depends on the tick’s 
size and itsthe duration of its stay on the host’s skin (4). 
Young forms, such as larvae, often go unnoticed because 
they are less than 1 mm in diameter and can release them-
selves or be accidentally removed before they are noticed. 
However, the larvae are also less contaminated.  Nymphs, 
the intermediate developmental stage of ticks, are the most 
typical carriers of infection. Nymphs have a higher per-
centage of infection with Bb, and even thoughtthough they 
are larger than larvae, are small enough to be less detect-
able and can stay on the skin of the host long enough (more 
than 24 hours) to transfer the infection. Adult ticks are 
larger (a few millimetres in diameter) after ira blood meal 
and can be observed easily and removed quickly; therefore, 
they usually do not have enough time to transfer Bb to the 
host. After infection with Bb, EM may be lacking in half of 
patients with LB (23), as was the case for our patient.
Pertaining to LNB, in almost half of the cases, the data 
on the tick bite and/or EM are missing (9). This gap in the 
available data makes the diagnosis of LNB difficult, but 
even the information about the tick bite, as was the case 
in our patient, can be misleading. It is considered that for 
the development of the third stage of LNB to occur, at 
least 6 months have tomust pass, which in our case was 
not fulfilled, thus indicating an earlier infection. Also, the 
tick bite, which occurred two months before the onset of 
symptoms, was not accompanied by the appearance of 
EM or other manifestations of the first stage of LB. There 
were no data on the manifestation of the second stage in 
our patient. Many patients with third stage LNB not only 
lack epidemiological data about the tick bite, but also lack 
information about the first/second stage clinical manifes-
tations (4). In such cases, there is a particular need for 
a good deferential diagnosis that encompasses multiple 
sclerosis, small vessels disease of the brain, neuropathy, 
and various other neurological, rheumatological and even 
psychiatric diseases (20).
An interesting point of our case is the simultaneous 
existence of two manifestations of late LNB—namely, pro-
gressive encephalomyelitis and neuropathy—and no signs 
of skin manifestations of acrodermatitis chronica atrophi-
cans. An immediate response of neuropathy to ceftriaxone 
is also intriguing, as usually one has to wait several months 
for a response to occur (21). The emergence of resistance to 
therapeutic antibiotics or recurrence of clinically expressed 
infection may be explained by multiple mechanisms. Dox-
ycycline is usually ineffective during the later stages of the 
disease, but dissemination leads to improvement, or there 
is a “decapitation” of infection, but it is not eradicated and 
consequently reappears. Less frequently, there might be a 
new infection, but then the time period between the two 
episodes of the disease necessarily has to be longer.
The value of ELISA IgG and IgM tests in the first 
steps of serological diagnosis has been confirmed. Posi-
tive findings are followed up by WB analysis, which 
serves as a confirmatory test because of its higher spe-
cificity (22). Typically, there is an increase in specific 
IgM antibodies in the beginning of the infection, and 
then the subsequent appearance of IgG antibodies, fol-
lowed by the disappearance of IgM and the persistence 
of IgG antibodies as a type of “immunological scar” (4). 
The persistence of IgM antibodies is rare but possible. 
Increased persistence of only IgM positivity is a false 
positive finding (19). The diagnosis of LB is primarily 
based on clinical findings, and serological results should 
be used only to confirm the diagnosis (24).
One of the controversies surrounding LNB involves 
CSF inflammatory syndrome. Inflammatory syndrome 
in CSF is commonly present in patients with meningitis 
and/or encephalitis in LNB. Although some authors con-
sider inflammatory syndrome in CSF mandatory for the 
diagnosis of LNB, the experience of other authors shows 
that it is not always present (25). A positive inflammatory 
response of pleocytosis and hyperproteinorachia sup-
ports the diagnosis of neuroinfection along with other 
data—in particular, the presence of specific Bb antibod-
ies, data on the tick bite and the corresponding clinical 
manifestations. The disappearance of inflammatory syn-
drome follows therapy. European criteria include pleocy-
tosis while the U.S. criteria does not include pleocytosis 
(25). While inpleocytosis is usually present in European 
LNB, the absence of pleocytosis can be explained by ear-
ly stage disease, immunosuppression, infection with Bb 
sensu stricto, or the presence of atypical genotypes.  In 
addition, some of our previous patients who fulfilled all of 
the other criteria for LNB and underwent successful anti-
biotic therapy did not have pleocytosis, so we propose the 
presentation of different microbiological characteristics 
of Bb genotypes in our region (26, 27). 
Polyneuropathy in LNB is rarely not accompanied with 
acrodermatitis chronica atrophicans (ACA) and usually 
has normal CSF findings. Polyneuropathy without ACA 
has been reported previously, but it occurs much more 
frequently in North America than in Europe. (28). This 
feature was also a distinctive symptom of our patient and 
is another argument in favour of the involvement of a less 
frequent Bb genotype.
In some patients with involvement of the brain, non-
specific white matter changes on MRI are found (10). In 
the diagnosis of LNB, MRI plays more of a role in exclud-
ing other causes than providing direct proof of the disease 
(10, 29), as was the case for our patient.  
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Ceftriaxone is the drug of choice for later stages of 
LB, especially the third stage of LNB (18). Although the 
published literature recommends courses of two to four 
weeks of intravenous cephtriaxone, in our experience, it is 
more efficient and safer to give 2 grams per day for longer 
courses of three to four weeks, so that the infection may be 
eradicated. AHowever, there are different opinions on this 
possibility, as there may be asymptomatic chronic persist-
ence of Bb even after therapy (19, 21).
Long courses of oral antibiotics, either alone or af-
ter parenteral therapy, are controversial, and there is not 
enough evidence to support its increased efficacy (18). 
Giving ceftriaxone, an antibiotic proven to be effective for 
the treatment of Bb, parenterally at a dose of 2 grams a 
day for three to four weeks, fulfils the old clinical maxim: 
give the appropriate drug, in the appropriate dose, long 
enough. After such treatment, infection recurrences are 
significantly lower, as was the case for our patient. Symp-
toms of successfully treated LNB can persist for up to 8 
months and, in the case of neuropathy, even for as long as 
two years (4). It is interesting that in our patient, a longer 
course of ceftriaxone led to the prompt withdrawal of both 
forms of late LNB, which co-existed. LNB can be success-
fully treated with adequate antibiotics (22). 
It should be emphasised that there is a logistical prob-
lem of diagnosing LNB in  smaller towns in which the 
availability of additional diagnostic methods is signifi-
cantly lower than in the large centres. Clinical diagnosis 
of neurological diseases is critical and requires vigilance 
on several levels: a high level of suspicion for LNB and a 
detailed disease history, as well as a detailed and accurate 
neurological examination. Medical histories should par-
ticularly address the epidemiological information about 
the tick bite, the presence of EM or other more specific 
manifestations of LB or LNB in  earlier stages, as in the case 
of patients such as ours, suffering from the third stage of 
LNB. The absence of data on the tick bite does not exclude 
diagnosis of LNB, so in such cases, one should insist on 
learning if there were possible trips to the countryside with 
greenery and travel to endemic areas where tick habitats 
exist (30). Serodiagnostics of LB takes two steps (9). The 
first step is an ELISA test for Bb specific IgG and IgM an-
tibodies in serum (preferably also in the CSL), and in the 
case of positive findings, a WB to detect IgG and IgM in 
serum (preferably in the CSL) can be performed to con-
firm the diagnosis. In the early stages, serological findings 
are negative and antibodies appear after about a month or 
two of repeated testing (4). Neurologists in smaller towns 
should establish cooperation in advance with one of the 
reference laboratories dealing with such diseases. Proving 
pleocytosis in CSF is controversial, as already discussed, 
and the presence of an increased number of lymphocytes 
supports LNB along with other positive findings, but the 
absence of pleocytosis does not make a case against LNB. 
Further diagnostic processing in the case of CNS involve-
ment should consist of brain and/or spinal cord MRI and, 
in the case of PNS, the involvement of EMNG performed 
on all four limbs. Other specific diagnostic procedures are 
not standard, even in the major centres of LNB, because of 
their lack of sensitivity and specificity (polymerase chain 
reaction - PCR, Bb isolation, etc.). PCR for clinical samples 
has demonstrated a low sensitivity for the diagnosis of LB 
using blood and CSF (29).
In our patient, this order was respected and LNB was 
proven, as well as its recurrence. LNB therapy is often a com-
plex process and requires an assessment of the whole set of 
circumstances (possible neurological and/or other comorbid-
ities, allergies to antibiotics, immune status, etc.) (23). 
Given the relative resistance of pathogen, we suggest 
as a reliable solution, therapy with ceftriaxone, two grams 
per day of intravenous infusion, preferably divided in two 
daily doses, for three to four weeks, less in second, more 
in the third stage. This therapy proved to be successful in 
our patient (Pavlović, 2012; Bhate, Schwartz, 2011) (21, 
22). We emphasise a rare coincidence of two events of the 
third stage of LNB, namely, progressive encephalomyelitis 
and peripheral neuritis in our patient, which complicates 
treatment.
CONCLUSION
Lyme disease manifests itself through a whole range 
of different clinical manifestations, especially in the skin, 
nervous system, heart and joints, and is divided into three 
stages. Our patient was a young woman in her thirties who 
presented with the third stage of LNB. She presented with 
a clinical picture of progressive encephalomyelitis and pe-
ripheral neuritis, which is a rarity. Serological tests are im-
portant in the diagnosis of LB but only along the clinical 
findings, and these tests are not, by themselves, the deter-
mining factor in establishing the aetiological diagnosis. An 
effort should be made in the case of suspected LNB cases 
to simultaneously examine CSL and serum for specific Bb 
antibodies. A positive ELISA test in the first step requires 
confirmation with a WB test. Additional testing includes 
MRI and/or EMNG. LNB treatment with intravenous cef-
triaxone or oral doxycycline depends on the stage of the 
disease. Due to the potential for less sensitivity of Bb, it is 
advisable to use ceftriaxone as antibiotic of first choice in 
all cases of proven LNB, as was confirmed in our patient.
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